Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Pulmonx Corp (NASDAQ: LUNG) closed at $1.76 down -8.33% from its previous closing price of $1.92. In other words, the price has decreased by -$8.33 from its previous closing price. On the day, 1.75 million shares were traded. LUNG stock price reached its highest trading level at $1.8298 during the session, while it also had its lowest trading level at $1.72.
Ratios:
For a deeper understanding of Pulmonx Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.62 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.80.
On March 10, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $17.
Citigroup Downgraded its Buy to Neutral on December 11, 2024, whereas the target price for the stock was revised from $17 to $7.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Williamson Steven S. sold 9,648 shares for $1.60 per share. The transaction valued at 15,437 led to the insider holds 358,967 shares of the business.
Joshi Mehul sold 7,936 shares of LUNG for $12,698 on Sep 02 ’25. The Chief Financial Officer & PAO now owns 208,489 shares after completing the transaction at $1.60 per share. On Sep 02 ’25, another insider, Rose Geoffrey Beran, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 6,543 shares for $1.60 each. As a result, the insider received 10,469 and left with 379,788 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 71713936 and an Enterprise Value of 44316940. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.79 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 0.489 whereas that against EBITDA is -0.821.
Stock Price History:
The Beta on a monthly basis for LUNG is 0.45, which has changed by -0.71929824 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, LUNG has reached a high of $9.37, while it has fallen to a 52-week low of $1.47. The 50-Day Moving Average of the stock is 4.33%, while the 200-Day Moving Average is calculated to be -55.25%.
Shares Statistics:
For the past three months, LUNG has traded an average of 2.38M shares per day and 12123460 over the past ten days. A total of 40.74M shares are outstanding, with a floating share count of 36.05M. Insiders hold about 11.54% of the company’s shares, while institutions hold 84.46% stake in the company. Shares short for LUNG as of 1760486400 were 1418511 with a Short Ratio of 0.60, compared to 1757894400 on 1781783. Therefore, it implies a Short% of Shares Outstanding of 1418511 and a Short% of Float of 5.1.
Earnings Estimates
. The current assessment of Pulmonx Corp (LUNG) involves the perspectives of 6.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.37 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.5 and -$1.58 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$1.39, with 6.0 analysts recommending between -$1.15 and -$1.58.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $20.9M this quarter.It ranges from a high estimate of $21.5M to a low estimate of $20M. As of. The current estimate, Pulmonx Corp’s year-ago sales were $20.39MFor the next quarter, 6 analysts are estimating revenue of $23.43M. There is a high estimate of $24.06M for the next quarter, whereas the lowest estimate is $23M.
A total of 6 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $91.77M, while the lowest revenue estimate was $90M, resulting in an average revenue estimate of $90.69M. In the same quarter a year ago, actual revenue was $83.79MBased on 6 analysts’ estimates, the company’s revenue will be $100.66M in the next fiscal year. The high estimate is $104.2M and the low estimate is $98.54M.
